- Home
- ABSI vs RGNX Comparison
ABSI vs RGNX Comparison
Compare ABSI & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- RGNX
- Stock Information
- Founded
- ABSI 2011
- RGNX 2008
- Country
- ABSI United States
- RGNX United States
- Employees
- ABSI N/A
- RGNX N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABSI Health Care
- RGNX Health Care
- Exchange
- ABSI Nasdaq
- RGNX Nasdaq
- Market Cap
- ABSI 505.4M
- RGNX 451.1M
- IPO Year
- ABSI 2021
- RGNX 2015
- Fundamental
- Price
- ABSI $3.79
- RGNX $10.62
- Analyst Decision
- ABSI Strong Buy
- RGNX Strong Buy
- Analyst Count
- ABSI 6
- RGNX 8
- Target Price
- ABSI $7.98
- RGNX $28.50
- AVG Volume (30 Days)
- ABSI 5.8M
- RGNX 499.3K
- Earning Date
- ABSI 11-11-2025
- RGNX 11-05-2025
- Dividend Yield
- ABSI N/A
- RGNX N/A
- EPS Growth
- ABSI N/A
- RGNX N/A
- EPS
- ABSI N/A
- RGNX N/A
- Revenue
- ABSI $4,138,000.00
- RGNX $155,782,000.00
- Revenue This Year
- ABSI $41.73
- RGNX $203.27
- Revenue Next Year
- ABSI $384.22
- RGNX $0.58
- P/E Ratio
- ABSI N/A
- RGNX N/A
- Revenue Growth
- ABSI 27.32
- RGNX 74.95
- 52 Week Low
- ABSI $2.01
- RGNX $5.04
- 52 Week High
- ABSI $6.33
- RGNX $12.22
- Technical
- Relative Strength Index (RSI)
- ABSI 73.13
- RGNX 64.66
- Support Level
- ABSI $2.48
- RGNX $9.55
- Resistance Level
- ABSI $3.70
- RGNX $11.00
- Average True Range (ATR)
- ABSI 0.24
- RGNX 0.50
- MACD
- ABSI 0.13
- RGNX 0.12
- Stochastic Oscillator
- ABSI 95.81
- RGNX 83.05
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.